Centene Corporation Sued for Securities Fraud

Strategic Insights -

Investors are suing Centene Corporation, a leading healthcare provider, after the company allegedly misstated its financial guidance, hiding the fact that the majority of its market was experiencing lower than expected enrollment growth and increased morbidity rates. The lawsuit seeks to recover losses for investors who purchased Centene securities between December 12, 2024, and July 1, 2025.

Key Takeaways:

  • Centene is facing a securities class-action lawsuit for allegedly violating federal securities laws by misstating its financial guidance.
  • The lawsuit claims that Centene knowingly hid the fact that its market was experiencing lower than expected enrollment growth and increased morbidity rates.
  • The price of Centene stock fell by $22.87 per share, or over 40%, after the company withdrew its previous guidance.
  • Investors who purchased Centene securities between December 12, 2024, and July 1, 2025, may be eligible to participate in the lawsuit.
  • The lawsuit is seeking to recover losses for investors who purchased Centene securities.
  • The case is pending in the U.S. District Court for the Southern District of New York, with investors having until September 8, 2025, to ask the court to be appointed to lead the case.

Statistics:

  • The lawsuit claims that Centene stock fell by $22.87 per share, or over 40%, from $56.65 per share to $33.78 per share on July 1, 2025.
  • The majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates.
  • Centene provides services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace.
  • The case is captioned: Lunstrum v. Centene Corporation et al., No. 25-cv-05659.

Sources:

  • Newsfile Corp. - August 18, 2025
  • Bleichmar Fonti & Auld LLP - Website (https://www.bfalaw.com)
  • Chamber USA - Top Plaintiff Law Firm
  • The Legal 500 - Top Plaintiff Law Firm
  • ISS SCAS - Top Plaintiff Law Firm
  • National Law Journal - Elite Trial Lawyers
  • Lawdragon - Top 500 Leading Plaintiff Financial Lawyers
  • Law360 - Titans of the Plaintiffs' Bar
  • Thomson Reuters - Super Lawyers
  • Tesla, Inc. Board of Directors (over $900 million recovered)
  • Teva Pharmaceutical Ind. Ltd. (over $420 million recovered)